^
    Back
    Association details:
    Biomarker:KIT exon 13 mutation
    Cancer:Melanoma
    Drug:Tasigna (nilotinib) (Bcr-abl tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    KIT mutation might occur in multiple "hotspots" across the gene and differ in their sensitivity to KIT inhibitors (eg, Imatinib, Sunitinib, Nilotinib). KIT exon 11 and exon 13 mutations (eg, W557, V559, L576P, K642E) appear to have a high level of sensitivity to KIT inhibition.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

    Excerpt:
    ...Presence of a c-Kit mutation of exon 9, 11 or 13, or mutations Y822D and mutations D820Y, Y823D of exon 17, as confirmed by the central laboratory 3....
    Trial ID:
    TEAM